IMV
IMV Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Market Cap: 9.63 Million
Primary Exchange: NASDAQ
Shares Outstanding: 11.7 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 1487 trading days
From: 2018-06-01 To: 2023-04-28
Lowest Point:
IMV Inc. to Present at Two Upcoming Investor Conferences
via: Business Wire at 2019-06-13 13:08:00:000
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor conferences in June: Raymond James Life Sciences and MedTech Conference Date : Wednesday, June 19, 2… read more...
IMV's DPX-Survivac shows encouraging action in mid-stage DLBCL study
via: SeekingAlpha at 2019-06-12 03:45:16:000
Updated results from a Phase 2 clinical trial, SPiReL , evaluating IMV's (NASDAQ: IMV ) lead candidate DPX-Survivac, combined with low-dose cyclophosphamide and Merck's (NYSE: MRK ) Keytruda (pembrolizumab), in patients with persistent or relapsed/refractory diffuse large B-cell lymphoma… read more...
New Phase 2 Clinical Trial Results Continue to Demonstrate Potential Clinical Benefit of IMV's DPX-Survivac in Combination with Merck's Keytruda in Patients with DLBCL
via: Business Wire at 2019-06-12 03:05:00:000
Complete radiologic responses linked to T cell activity observed in two of first six evaluable patients IMV to host investor conference call and webcast on June 12, 2019 at 8:00 am ET IMV Inc. (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today announced up… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|